Extracorporeal treatment (ECTR) is used in selected severe poisonings to enhance toxin elimination and, in some cases, provide temporary organ support. Modalities include intermittent hemodialysis, continuous renal replacement therapy, and sorbent-based hemoperfusion or hemoadsorption, each with distinct mechanisms and toxicokinetic implications. This narrative review summarizes modality-specific and toxin-specific evidence, operational treatment characteristics, patient-centered and toxicokinetic outcomes, safety considerations, and scenarios in which ECTR should be withheld, and proposes a practical five-step bedside algorithm. Sources were identified through targeted searches of PubMed/MEDLINE and Google Scholar, supplemented by Extracorporeal Treatments in Poisoning (EXTRIP) consensus documents, reference-list screening, and author expertise. The evidence base varies substantially across toxins. For several pharmaceutical poisonings, EXTRIP provides the most actionable guidance on indications, preferred modality, and stopping criteria, while recommending against ECTR for digoxin and methotrexate. Outside these consensus-guided settings, the largest experience with sorbent therapies concerns paraquat and organophosphorus/carbamate poisoning, although the literature is regionally concentrated and predominantly observational. In paraquat poisoning, hemoadsorption-containing strategies have been associated with improved survival in observational cohorts, while pharmacokinetic studies support early and repeated treatment in selected patients because of ongoing toxin removal and post-treatment rebound. In organophosphorus/carbamate poisoning, comparative studies suggest possible benefit in severe presentations, but certainty remains low. In diquat poisoning, recent reports emphasize concentration-directed extracorporeal strategies. Evidence for other toxins is largely limited to feasibility, toxin removal, and case-based experience. ECTR should therefore be regarded as a toxin-specific therapeutic toolbox rather than a uniform intervention. Where available, EXTRIP recommendations should guide practice. Otherwise, modality selection should integrate toxicokinetic plausibility, clinical severity, feasibility, and safety. Prospective studies using standardized prescriptions and clinically meaningful endpoints are needed.
Full article